Researchers examining 133 prostate cancer samples of various grades from 41 men have identified four genes whose expression was correlated with the reduced citrate and increased choline containing compound (ChoCC) levels characteristic of prostate cancer. ACLY (P = 0.003) and ACON (P <0.001) expression were associated with reduced citrate levels whereas PLA2G7 (P <0.001) and CHKA (P = 0.002) were associated with increased ChoCCs. These genes might represent potential targets for therapy.